Genus Oncology has dosed the first patient in a Phase I trial to evaluate its GO-203-2c compound as a treatment for solid tumours.
The prospective, open-label trial is designed to determine the safety, tolerability and potential anti-tumour activity of GO-203-2c.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Up to 40 patients will be enrolled at multiple clinical sites.
GO-203-2c is the optimised lead peptide drug candidate, synthesised to target MUC1, an oncoprotein that is over-expressed in many human carcinomas.
Genus has also filed an investigational new drug application with the US Food & Drug Administration.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
